Status
Conditions
About
OBJECTIVES: I. Correlate clinical outcome with cerebral glucose metabolism in patients with Huntington's disease (HD) and their at-risk relatives.
II. Evaluate the efficacy of cerebral glucose metabolism in observing the pathophysiologic development of HD, monitoring responses to experimental therapy, and predicting HD genotype.
III. Identify, define, and describe the natural history of pathophysiologic lesions in HD.
IV. Characterize the genotypic and phenotypic expression of the HD gene.
Full description
PROTOCOL OUTLINE: Participants are screened for Huntington's disease, including cerebral glucose metabolism assessment and genetic testing.
Studies include a detailed family history and neurologic, psychometric, and neurobehavioral evaluations. Imaging includes positron emission tomography with fluorodeoxyglucose and brain magnetic resonance imaging.
A genotype assessment is performed; genetic results are not disclosed to patients or relatives.
Sex
Volunteers
Inclusion and exclusion criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
At least 4 weeks since other HD treatment, e.g.:
--Patient Characteristics--
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal